Hologic, Inc. (HOLX) EV/Sales Ratio: 4.25x
Is Hologic, Inc.’s EV/Sales ratio high or low?
Hologic, Inc.'s EV/Sales ratio of 4.25x is in line with its 5-year average of 4.15x, around the middle of its 5-year range (3.04x–5.24x).
As of Thursday, June 11, 2026. 5.84% above its 12-month average of 4.02x.
HOLX EV/Sales Ratio Chart
HOLX Average EV/Sales Ratio Chart
HOLX Current vs Average EV/Sales Ratio Chart
HOLX EV/Sales Ratio Metrics
EV/SALES RATIO
4.25x
EV/SALES RATIO AVG TTM
4.02x
EV/SALES RATIO AVG 3Y
4.39x
EV/SALES RATIO AVG 5Y
4.15x
EV/SALES RATIO AVG 10Y
4.50x
EV/SALES RATIO AVG 15Y
4.39x
EV/SALES RATIO AVG 20Y
4.41x
CURRENT VS TTM AVG
+5.84%
CURRENT VS 3Y AVG
-3.21%
CURRENT VS 5Y AVG
+2.31%
CURRENT VS 10Y AVG
-5.55%
CURRENT VS 15Y AVG
-3.09%
CURRENT VS 20Y AVG
-3.73%
HOLX Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hologic, Inc. (HOLX) | $16.97B | 4.25x | 4.02x | 4.39x | 4.15x |
| Moderna, Inc. (MRNA) | $18.71B | 8.10x | 5.96x | 5.02x | 6.82x |
| Align Technology, Inc. (ALGN) | $12.27B | 2.75x | 2.73x | 4.07x | 5.91x |
| BioNTech SE (BNTX) | $22.39B | 3.24x | 4.19x | 3.71x | 3.49x |
| Mettler-Toledo International Inc. (MTD) | $22.82B | 6.13x | 7.35x | 7.51x | 8.18x |
| Waters Corporation (WAT) | $23.21B | 9.27x | 7.03x | 7.13x | 7.32x |
| Baxter International Inc. (BAX) | $10.49B | 1.60x | 1.72x | 2.17x | 2.64x |
| Charles River Laboratories International, Inc. (CRL) | $8.94B | 2.97x | 2.79x | 3.02x | 3.79x |
| Bio-Rad Laboratories, Inc. (BIO) | $7.92B | 3.41x | 3.41x | 3.67x | 4.57x |
| Veeva Systems Inc. (VEEV) | $26.31B | 7.65x | 12.50x | 13.33x | 15.70x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Hologic, Inc. EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Hologic, Inc. EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Hologic, Inc. (HOLX)?
- The EV/Sales ratio for HOLX stock is 4.25x.
- Is Hologic, Inc.'s EV/Sales ratio high or low?
- Hologic, Inc.'s EV/Sales ratio of 4.25x is in line with its 5-year average of 4.15x, around the middle of its 5-year range (3.04x–5.24x).
- What is the TTM average EV/Sales ratio for Hologic, Inc. (HOLX)?
- The TTM average EV/Sales ratio for HOLX stock is 4.02x.
- What is the 3Y average EV/Sales ratio for Hologic, Inc. (HOLX)?
- The 3Y average EV/Sales ratio for HOLX stock is 4.39x.
- What is the 5Y average EV/Sales ratio for Hologic, Inc. (HOLX)?
- The 5Y average EV/Sales ratio for HOLX stock is 4.15x.
- What is the 10Y average EV/Sales ratio for Hologic, Inc. (HOLX)?
- The 10Y average EV/Sales ratio for HOLX stock is 4.50x.
- What is the 15Y average EV/Sales ratio for Hologic, Inc. (HOLX)?
- The 15Y average EV/Sales ratio for HOLX stock is 4.39x.
- What is the 20Y average EV/Sales ratio for Hologic, Inc. (HOLX)?
- The 20Y average EV/Sales ratio for HOLX stock is 4.41x.
Hologic, Inc. EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-04-07 | 4.25x |
| 2026-04-06 | 4.25x |
| 2026-04-02 | 4.23x |
| 2026-04-01 | 4.22x |
| 2026-03-31 | 4.22x |
| 2026-03-30 | 4.22x |
| 2026-03-27 | 4.23x |
| 2026-03-26 | 4.23x |
| 2026-03-25 | 4.22x |
| 2026-03-24 | 4.22x |
| 2026-03-23 | 4.23x |
| 2026-03-20 | 4.21x |
| 2026-03-19 | 4.21x |
| 2026-03-18 | 4.20x |
| 2026-03-17 | 4.19x |
| 2026-03-16 | 4.20x |
| 2026-03-13 | 4.20x |
| 2026-03-12 | 4.20x |
| 2026-03-11 | 4.21x |
| 2026-03-10 | 4.22x |
| 2026-03-09 | 4.22x |
| 2026-03-06 | 4.23x |
| 2026-03-05 | 4.23x |
| 2026-03-04 | 4.23x |
| 2026-03-03 | 4.22x |
| 2026-03-02 | 4.22x |
| 2026-02-27 | 4.21x |
| 2026-02-26 | 4.20x |
| 2026-02-25 | 4.21x |
| 2026-02-24 | 4.21x |
| 2026-02-23 | 4.21x |
| 2026-02-20 | 4.21x |
| 2026-02-19 | 4.20x |
| 2026-02-18 | 4.20x |
| 2026-02-17 | 4.20x |
| 2026-02-13 | 4.19x |
| 2026-02-12 | 4.19x |
| 2026-02-11 | 4.20x |
| 2026-02-10 | 4.20x |
| 2026-02-09 | 4.19x |
| 2026-02-06 | 4.18x |
| 2026-02-05 | 4.17x |
| 2026-02-04 | 4.17x |
| 2026-02-03 | 4.17x |
| 2026-02-02 | 4.18x |
| 2026-01-30 | 4.19x |
| 2026-01-29 | 4.19x |
| 2026-01-28 | 4.30x |
| 2026-01-27 | 4.30x |
| 2026-01-26 | 4.30x |
| 2026-01-23 | 4.29x |
| 2026-01-22 | 4.30x |
| 2026-01-21 | 4.30x |
| 2026-01-20 | 4.30x |
| 2026-01-16 | 4.29x |
| 2026-01-15 | 4.29x |
| 2026-01-14 | 4.30x |
| 2026-01-13 | 4.28x |
| 2026-01-12 | 4.28x |
| 2026-01-09 | 4.28x |
| 2026-01-08 | 4.28x |
| 2026-01-07 | 4.29x |
| 2026-01-06 | 4.29x |
| 2026-01-05 | 4.28x |
| 2026-01-02 | 4.27x |
| 2025-12-31 | 4.26x |
| 2025-12-30 | 4.27x |
| 2025-12-29 | 4.26x |
| 2025-12-26 | 4.26x |
| 2025-12-24 | 4.26x |
| 2025-12-23 | 4.28x |
| 2025-12-22 | 4.29x |
| 2025-12-19 | 4.29x |
| 2025-12-18 | 4.29x |
| 2025-12-17 | 4.29x |
| 2025-12-16 | 4.29x |
| 2025-12-15 | 4.30x |
| 2025-12-12 | 4.29x |
| 2025-12-11 | 4.28x |
| 2025-12-10 | 4.28x |
| 2025-12-09 | 4.29x |
| 2025-12-08 | 4.28x |
| 2025-12-05 | 4.29x |
| 2025-12-04 | 4.28x |
| 2025-12-03 | 4.29x |
| 2025-12-02 | 4.28x |
| 2025-12-01 | 4.28x |
| 2025-11-28 | 4.29x |
| 2025-11-26 | 4.28x |
| 2025-11-25 | 4.28x |
| 2025-11-24 | 4.28x |
| 2025-11-21 | 4.26x |
| 2025-11-20 | 4.24x |
| 2025-11-19 | 4.25x |
| 2025-11-18 | 4.24x |
| 2025-11-17 | 4.33x |
| 2025-11-14 | 4.33x |
| 2025-11-13 | 4.34x |
| 2025-11-12 | 4.36x |
| 2025-11-11 | 4.36x |
| 2025-11-10 | 4.34x |
| 2025-11-07 | 4.33x |
| 2025-11-06 | 4.33x |
| 2025-11-05 | 4.34x |
| 2025-11-04 | 4.33x |
| 2025-11-03 | 4.33x |
| 2025-10-31 | 4.32x |
| 2025-10-30 | 4.32x |
| 2025-10-29 | 4.32x |
| 2025-10-28 | 4.33x |
| 2025-10-27 | 4.32x |
| 2025-10-24 | 4.33x |
| 2025-10-23 | 4.32x |
| 2025-10-22 | 4.32x |
| 2025-10-21 | 4.32x |
| 2025-10-20 | 4.21x |
| 2025-10-17 | 4.09x |
| 2025-10-16 | 4.02x |
| 2025-10-15 | 3.94x |
| 2025-10-14 | 3.87x |
| 2025-10-13 | 3.85x |
| 2025-10-10 | 3.98x |
| 2025-10-09 | 4.03x |
| 2025-10-08 | 4.01x |
| 2025-10-07 | 3.98x |
| 2025-10-06 | 3.95x |
| 2025-10-03 | 4.00x |
| 2025-10-02 | 3.99x |
| 2025-10-01 | 3.94x |
| 2025-09-30 | 3.96x |
| 2025-09-29 | 3.94x |
| 2025-09-26 | 3.95x |
| 2025-09-25 | 3.87x |
| 2025-09-24 | 3.90x |
| 2025-09-23 | 3.97x |
| 2025-09-22 | 3.95x |
| 2025-09-19 | 3.90x |
| 2025-09-18 | 4.01x |
| 2025-09-17 | 4.00x |
| 2025-09-16 | 3.73x |
| 2025-09-15 | 3.76x |
| 2025-09-12 | 3.79x |
| 2025-09-11 | 3.90x |
| 2025-09-10 | 3.85x |
| 2025-09-09 | 3.92x |
| 2025-09-08 | 3.91x |
| 2025-09-05 | 3.92x |
| 2025-09-04 | 3.90x |
| 2025-09-03 | 3.89x |
| 2025-09-02 | 3.91x |
| 2025-08-29 | 3.94x |
| 2025-08-28 | 3.91x |
| 2025-08-27 | 3.92x |
| 2025-08-26 | 3.91x |
| 2025-08-25 | 3.94x |
| 2025-08-22 | 4.01x |
| 2025-08-21 | 3.94x |
| 2025-08-20 | 4.03x |
| 2025-08-19 | 3.98x |
| 2025-08-18 | 3.95x |
| 2025-08-15 | 3.98x |
| 2025-08-14 | 3.99x |
| 2025-08-13 | 4.05x |
| 2025-08-12 | 3.99x |
| 2025-08-11 | 3.99x |
| 2025-08-08 | 3.99x |
| 2025-08-07 | 3.99x |
| 2025-08-06 | 3.93x |
| 2025-08-05 | 3.98x |
| 2025-08-04 | 3.99x |
| 2025-08-01 | 3.94x |
| 2025-07-31 | 3.92x |
| 2025-07-30 | 3.92x |
| 2025-07-29 | 3.98x |
| 2025-07-28 | 3.96x |
| 2025-07-25 | 4.00x |
| 2025-07-24 | 3.98x |
| 2025-07-23 | 3.97x |
| 2025-07-22 | 3.94x |
| 2025-07-21 | 3.84x |
| 2025-07-18 | 3.86x |
| 2025-07-17 | 3.86x |
| 2025-07-16 | 3.85x |
| 2025-07-15 | 3.82x |
| 2025-07-14 | 3.90x |
| 2025-07-11 | 3.96x |
| 2025-07-10 | 4.02x |
| 2025-07-09 | 3.97x |
| 2025-07-08 | 3.91x |
| 2025-07-07 | 3.88x |
| 2025-07-03 | 3.91x |
| 2025-07-02 | 3.94x |
| 2025-07-01 | 3.94x |
| 2025-06-30 | 3.93x |
| 2025-06-27 | 3.92x |
| 2025-06-26 | 3.92x |
| 2025-06-25 | 3.88x |
| 2025-06-24 | 3.91x |
| 2025-06-23 | 3.89x |
| 2025-06-20 | 3.89x |
| 2025-06-18 | 3.86x |
| 2025-06-17 | 3.87x |
| 2025-06-16 | 3.93x |
| 2025-06-13 | 3.90x |
| 2025-06-12 | 3.93x |
| 2025-06-11 | 3.89x |
| 2025-06-10 | 3.93x |
| 2025-06-09 | 3.89x |
| 2025-06-06 | 3.88x |
| 2025-06-05 | 3.81x |
| 2025-06-04 | 3.78x |
| 2025-06-03 | 3.81x |
| 2025-06-02 | 3.75x |
| 2025-05-30 | 3.76x |
| 2025-05-29 | 3.80x |
| 2025-05-28 | 3.85x |
| 2025-05-27 | 3.76x |
| 2025-05-23 | 3.32x |
| 2025-05-22 | 3.33x |
| 2025-05-21 | 3.35x |
| 2025-05-20 | 3.44x |
| 2025-05-19 | 3.44x |
| 2025-05-16 | 3.46x |
| 2025-05-15 | 3.40x |
| 2025-05-14 | 3.38x |
| 2025-05-13 | 3.48x |
| 2025-05-12 | 3.57x |
| 2025-05-09 | 3.46x |
| 2025-05-08 | 3.42x |
| 2025-05-07 | 3.38x |
| 2025-05-06 | 3.25x |
| 2025-05-05 | 3.23x |
| 2025-05-02 | 3.31x |
| 2025-05-01 | 3.48x |
| 2025-04-30 | 3.53x |
| 2025-04-29 | 3.54x |
| 2025-04-28 | 3.53x |
| 2025-04-25 | 3.52x |
| 2025-04-24 | 3.54x |
| 2025-04-23 | 3.53x |
| 2025-04-22 | 3.53x |
| 2025-04-21 | 3.46x |
| 2025-04-17 | 3.50x |
| 2025-04-16 | 3.43x |
| 2025-04-15 | 3.51x |
| 2025-04-14 | 3.57x |
| 2025-04-11 | 3.51x |
| 2025-04-10 | 3.47x |
| 2025-04-09 | 3.60x |
| 2025-04-08 | 3.55x |
| 2025-04-07 | 3.71x |
| 2025-04-04 | 3.69x |
| 2025-04-03 | 3.73x |
| 2025-04-02 | 3.67x |
| 2025-04-01 | 3.72x |
| 2025-03-31 | 3.74x |
| 2025-03-28 | 3.71x |
| 2025-03-27 | 3.77x |
| 2025-03-26 | 3.72x |
| 2025-03-25 | 3.68x |
Showing the most recent 260 of 5,030 data points. The chart above shows the full history.
Related Metrics
About Hologic, Inc.
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Paul Malenchini